After cataract surgery, a mild increase of foveal thickness without impact on visual acuity could be observed. This increase may be due to both subclinical changes and to influence of changes in media opacity on the measurement technique. Surgical and biometric parameters such as phacotime and energy and axial length did not correlate to the degree of macular thickening.

The flap architecture created with the femtosecond laser was more regular and accurate than the flap architecture created with the microkeratome.

Indocyanine green-assisted macular surgery might lead to optic nerve atrophy in the long-term and persistent VFDs. In addition, new VFDs may occur in the postoperative course. An affection of color vision also underlines the potential impact of ICG on visual function. A long-term observation of patients after ICG-assisted vitrectomy seems mandatory to reliably detect functional adverse events.

<i>Purpose:</i> To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). <i>Methods:</i> Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (>21 mm Hg) treated with a single intracameral injection of bevacizumab over a minimum follow-up of 6 months. The endpoint of the study was the need for retreatment due to recurrence of raised intraocular pressure (IOP). Secondary outcome was the course of visual acuity (VA) and IOP over 6 months. <i>Results:</i> A Kaplan-Meier calculation revealed a mean duration of the treatment effect of 23 ± 4.4 days. Compared to mean IOP before treatment (26.3 mm Hg), decreases to 17.5 mm Hg at 1 week after treatment (p < 0.002) and to 17.1 mm Hg (p < 0.005) at 6 months following a single injection were seen. At 6 months, additional treatment was performed in 87.5% (n = 21) of eyes. VA remained stable or improved in 75% (n = 18) of all cases. <i>Conclusion:</i> The IOP-lowering effect of intracameral bevacizumab can be seen 1 week after the injection, but is limited to a period of approximately 3 weeks. However, the fast and effective response to intracameral bevacizumab injection opens a time window for additional treatments, which are often necessary.

Purpose: Our purpose was to report a case of anterior optic neuropathy with pupillary edema in a patient treated with the TNF-α-antagonist adalimumab. Methods: We report the case of a 60-year-old woman with optic neuropathy in 1 eye after 6 months of treatment with adalimumab. Results: The patient developed decreased visual acuity of the left eye. The ocular findings were left optic disc swelling and bleeding at the rim, superior visual field depression in both eyes and left afferent pupillary defect. Adalimumab was discontinued and the visual acuity recovered slowly. Conclusions: Like infliximab, the modern TNF-α antagonist adalimumab is associated with optic neuropathy. Ophthalmologists should thus be alert when seeing patients treated with adalimumab.

A significant visual improvement was observed immediately after cataract surgery using the combination of topical and intracameral anaesthesia. 75 % of the patients reached a UCVA, which permitted sufficient visual function for mobility and orientation. Thus, the rapid recovery of visual function suggests an increased safety, particularly for out-patient surgery.

SIGNIFICANCE Two fungal endophthalmitis cases demonstrate safety and efficiency of intravitreal caspofungin as a new therapy option in fungal endophthalmitis. PURPOSE The purpose of this study was to evaluate the intravitreal application of caspofungin for the treatment of fungal endophthalmitis because rising resistance to voriconazole and amphotericin B leads to a need for new antifungal therapy options. CASE REPORT Initially, both patients with fungal endophthalmitis underwent pars plana vitrectomy. Microbiological analysis revealed Aspergillus terreus and Candida dubliniensis, which both possess atypical resistance patterns. Caspofungin has a low bioavailability in the eye when given systemically. It was injected intravitreally into the eyes affected by fungal endophthalmitis. An injection of 100 μg of caspofungin in a volume 0.1 mL was applied repeatedly. Clinical parameters were recorded. Both eyes were stabilized by the treatment. Finally, the intraocular infections with atypical mycotic agents were eliminated. Visual acuity improved to 0.4 logMAR (20/50 Snellen) in the first case and to 1.0 logMAR (20/200 Snellen) in the second case. During the treatment course, we have not seen any toxic effects or damage of intraocular structures related to the intravitreal administration of caspofungin. CONCLUSIONS In summary, intravitreal caspofungin was effective and well tolerated in both cases. Therefore, caspofungin seems to be a safe and effective intravitreal alternative to voriconazole and amphotericin B in fungal endophthalmitis.

Mit dem vermehrten Einsatz von Immun-Checkpoint-Inhibitoren in der Behandlung verschiedener, häufig bisher nicht therapierbarer Tumorerkrankungen treten immer häufiger autoimmune Nebenwirkungen auf. Hierzu zählt auch die Uveitis. Die medikamenteninduzierte Uveitis stellt somit ein seltenes, jedoch zunehmend auftretendes Krankheitsbild dar. ▶ Abb. 1 (a = rechts, b = links): Spaltlampenfotografie des Glaskörpers. Es finden sich beidseits Entzündungszellen und "snow balls".